Inaccuracies in the recently published review on mirabegron.
作者信息
Siddiqui Emad
机构信息
Astellas Pharma Europe Ltd., Chertsey, UK,
出版信息
Int Urogynecol J. 2014 Feb;25(2):295. doi: 10.1007/s00192-013-2274-9. Epub 2013 Dec 7.
Abstract
摘要
相似文献
1
Inaccuracies in the recently published review on mirabegron.最近发表的关于米拉贝隆的综述中的不准确之处。
Int Urogynecol J. 2014 Feb;25(2):295. doi: 10.1007/s00192-013-2274-9. Epub 2013 Dec 7.
2
Mirabegron for overactive bladder.米拉贝隆用于治疗膀胱过度活动症。
Nurse Pract. 2012 Dec 10;37(12):9-10. doi: 10.1097/01.NPR.0000422213.00175.5d.
3
Profile of mirabegron in the treatment of overactive bladder: place in therapy.米拉贝隆治疗膀胱过度活动症的概况：在治疗中的地位。
Drug Des Devel Ther. 2017 Feb 20;11:463-467. doi: 10.2147/DDDT.S101630. eCollection 2017.
4
Mirabegron (Myrbetriq) for overactive bladder.米拉贝隆（贝坦利）用于治疗膀胱过度活动症。
Med Lett Drugs Ther. 2013 Feb 18;55(1410):13-5.
5
Re: The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.回复：β3肾上腺素能受体激动剂米拉贝隆治疗老年患者膀胱过度活动症症状的疗效和耐受性
J Urol. 2015 Mar;193(3):947. doi: 10.1016/j.juro.2014.12.072. Epub 2014 Dec 18.
6
Re: β3-adrenoreceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men.回复：β3肾上腺素能受体激动剂米拉贝隆对对抗胆碱能治疗无反应或与男性良性前列腺增生相关的膀胱过度活动症有效。
J Urol. 2014 May;191(5):1344-6. doi: 10.1016/j.juro.2014.02.067. Epub 2014 Feb 22.
7
[Idiopathic overactive bladder: What to do in case of anticholinergic failure?].[特发性膀胱过度活动症：抗胆碱能药物治疗失败时该怎么办？]
Prog Urol. 2015 Jun;25(8):497-8. doi: 10.1016/j.purol.2015.02.002. Epub 2015 Mar 5.
8
Mirabegron as a new class of oral drug for overactive bladder syndrome: many positive perspectives, some concerns.米拉贝隆作为治疗膀胱过度活动症的新型口服药物：诸多积极方面，也存在一些担忧。
Eur Urol. 2013 Feb;63(2):306-8. doi: 10.1016/j.eururo.2012.11.024. Epub 2012 Nov 16.
9
Drug therapy for an overactive bladder.膀胱过度活动症的药物治疗。
Womens Health (Lond). 2015 Jul;11(4):445-8. doi: 10.2217/whe.15.31. Epub 2015 Aug 4.
10
Urinary incontinence: Patient-reported outcome measures favour use of mirabegron in patients with OAB.尿失禁：患者报告的结局指标支持在膀胱过度活动症患者中使用米拉贝隆。
Nat Rev Urol. 2015 Nov;12(11):593. doi: 10.1038/nrurol.2015.223. Epub 2015 Sep 8.
本文引用的文献
1
What do we know and not know about mirabegron, a novel β3 agonist, in the treatment of overactive bladder?关于新型β3激动剂米拉贝隆治疗膀胱过度活动症，我们了解什么以及不了解什么？
Int Urogynecol J. 2014 Feb;25(2):165-70. doi: 10.1007/s00192-013-2161-4. Epub 2013 Aug 7.
2
Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.米拉贝隆治疗膀胱过度活动症的随机、双盲、阳性药物对照 3 期临床试验：12 个月安全性和疗效评估
Eur Urol. 2013 Feb;63(2):296-305. doi: 10.1016/j.eururo.2012.10.048. Epub 2012 Nov 6.
Zotero 插件